Insys files for bankruptcy on the heels of $225M kickback settlement with the feds

Insys Therapeutics Subsys
Insys will look to sell most of its assets as part of a Chapter 11 bankruptcy filing. (Insys Therapeutics)

When Insys Therapeutics settled with the feds for a whopping $225 million last week on federal kickback charges, the drugmaker hoped it had put its troubled past behind it. Turns out that was only the tip of the iceberg for the embattled opioid maker.

Insys filed for Chapter 11 bankruptcy Monday on the heels of an agreement with the Department of Justice to shell out civil and criminal penalties to tie up charges the company paid doctors to boost scripts of its powerful fentanyl spray Subsys.

The Arizona-based drugmaker will look to sell almost all of its assets within 90 days without interrupting payments to vendors and suppliers or normal operations, the company said in a release.

“After conducting a thorough review of available strategic alternatives, we determined that a court-supervised sale process is the best course of action to maximize the value of our assets and address our legacy legal challenges in a fair and transparent manner,” Insys CEO Andrew Long said.

In premarket trading Monday, Insys’ share prices had declined roughly 60% since Friday’s market close to 52 cents per share. Since its six-month high of $6.50 per share on March 1, the drugmaker’s share prices have fallen 92%.

RELATED: Insys, looking for a clean slate, agrees to pay $225M in Subsys kickback probe

Insys’ bankruptcy filing caps a troubled period for the drugmaker after it agreed to five years of deferred prosecution in its settlement agreement and watched its founder and former CEO John Kapoor go down on federal racketeering charges in May.

Kapoor was found guilty by a Boston jury of driving a scheme to reward sales managers for wining and dining physicians to boost Subsys sales, a strategy federal prosecutors said exacerbated the nation’s opioid epidemic. Kapoor was the first C-level executive to be held directly responsible for his company’s role in the driving the crisis.

RELATED: Feds join lawsuits claiming Insys used strip club visits, super-doses and more to boost Subsys sales

Insys’ executive-driven bribery scheme included allegations that doctors were treated to expensive seafood dinners and strip club visits as part of a sham speaker program directed by the company’s marketing team. The former head of that program, sales vice president Alec Burlakoff, reached a plea agreement on fraud charges in federal court and is currently working with the Arizona attorney general’s office in their ongoing investigation of Kapoor.

Burlakoff and Kapoor were just two of the company’s team members knocked by federal prosecutors. Another former CEO, Mark Babich, pleaded guilty to mail fraud charges and testified against Kapoor in his trial. The federal probe also nabbed former Insys sales managers involved in the scheme and five Manhattan doctors who were also implicated.

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.